Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy

TerminatedOBSERVATIONAL
Enrollment

29

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

December 8, 2020

Study Completion Date

December 8, 2020

Conditions
Pancreatic Cancer
Trial Locations (15)

15232

UPMC Hillman Cancer Center, Pittsburgh

32610

UF Health Cancer Center, Gainesville

33612

Moffitt Cancer Center, Tampa

40292

University of Louisville, Louisville

46526

Indiana University Health Goshen Center for Cancer Care, Goshen

53792

University of Wisconsin, Madison

60201

NorthShore University HealthSystem, Evanston

60611

Northwestern University, Chicago

63110

Washington University, St Louis

75390

UT Southwestern Medical Center, Dallas

77030

Baylor College of Medicine, Houston

78229

UT Health Cancer Center, San Antonio

90048

Cedars-Sinai Medical Center, Los Angeles

94305

Stanford University Cancer Center, Palo Alto

97239

Oregon Health and Science University, Portland

Sponsors
All Listed Sponsors
lead

NewLink Genetics Corporation

INDUSTRY

NCT03165188 - Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy | Biotech Hunter | Biotech Hunter